trending Market Intelligence /marketintelligence/en/news-insights/trending/sKGJ3SVu1JPen2AxJFVXJA2 content esgSubNav
In This List

Illumina's $1.2B Pacific Biosciences merger waiting period extended by FTC

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


Illumina's $1.2B Pacific Biosciences merger waiting period extended by FTC

The waiting period to complete Illumina Inc.'s $1.2-billion acquisition of Pacific Biosciences of California Inc. will be extended after the U.S. Federal Trade Commission requested additional information from the companies.

San Diego-based Illumina and gene sequencing company Pacific Biosciences said the waiting period for the completion of the merger will begin after being in compliance with FTC's request.

In November 2018, Illumina said it will acquire Menlo Park, Calif.-based Pacific Biosciences for $8 per share in an all-cash transaction.

The companies still expect the merger will be completed by midyear.